SK Pharmteco Expands CDMO Footprint with Multimodal Showcase at CPHI Milan
Event summary
- SK Pharmteco will attend CPHI Milan (Oct 8–10, 2026) to showcase its expanded CDMO capabilities in small molecules, peptides, and viral vectors.
- The company is sponsoring the CPHI Sustainability Summit and Sustainability Theater, highlighting its commitment to sustainable pharmaceutical supply chains.
- SK Pharmteco’s global network spans North America, Europe, and Asia, supporting end-to-end development and commercialization of complex therapies.
- Key focus areas include small molecule APIs, peptide therapeutics, and viral vector services through its SKyvec™ platform.
The big picture
SK Pharmteco’s participation in CPHI Milan underscores the growing importance of multimodal CDMO capabilities in the pharmaceutical industry. As biopharmaceutical companies increasingly seek partners with end-to-end development and manufacturing solutions, SK Pharmteco’s global infrastructure and sustainability focus position it to capture a larger share of the outsourced pharmaceutical production market. The company’s strategic alignment with industry trends in sustainability and complex therapy development highlights its role as a key player in the evolving CDMO landscape.
What we're watching
- Capacity Utilization
- How SK Pharmteco’s expanded global footprint will impact its ability to secure long-term contracts and sustain revenue growth.
- Sustainability Leadership
- Whether the company’s sustainability initiatives will differentiate it in a competitive CDMO market.
- Execution Risk
- The pace at which SK Pharmteco can integrate its multimodal capabilities to meet client demands for complex therapies.
Related topics